• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Cardinal Health Reports Third Quarter Fiscal Year 2025 Results and Raises Fiscal Year 2025 Outlook

    5/1/25 6:45:00 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care
    Get the next $CAH alert in real time by email
    • Revenue was flat at $54.9 billion; revenue increased 19% excluding the impact of the previously communicated customer contract expiration
    • GAAP1 operating earnings were $730 million; GAAP diluted EPS was $2.10
    • Non-GAAP operating earnings increased 21% to $807 million, driven by segment profit growth across all of the company's operating segments; non-GAAP diluted EPS increased 13% to $2.35
    • Fiscal year 2025 non-GAAP EPS guidance2 raised and narrowed to $8.05 to $8.15, from $7.85 to $8.00
    • GI Alliance announces expansion into urology specialty therapeutic area

    DUBLIN, Ohio, May 1, 2025 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today reported third quarter fiscal year 2025 revenues of $54.9 billion, flat to the third quarter of fiscal year 2024. Third quarter revenue increased 19% excluding the impact of the previously communicated customer contract expiration. Third quarter GAAP operating earnings increased to $730 million and GAAP diluted earnings per share (EPS) were $2.10. Third quarter non-GAAP operating earnings increased 21% to $807 million, driven by segment profit growth across all of the company's operating segments. Non-GAAP diluted EPS increased 13% to $2.35, reflecting the increase in non-GAAP operating earnings and a lower share count, partially offset by an increase in interest and other expense primarily due to previously anticipated financing costs related to recent acquisitions and a higher non-GAAP effective tax rate.

    Cardinal Health Logo (PRNewsfoto/Cardinal Health)

    "Our strong momentum continued into our third quarter as our team's ongoing focus on operational execution and value creation led to excellent financial results," said Jason Hollar, CEO of Cardinal Health. "I am delighted to see the broad-based performance, with all five of our operating segments contributing to our strong growth. We are pleased to raise our fiscal 2025 guidance demonstrating the strength and resilience of Cardinal Health."

    Q3 FY25 summary



    Q3 FY25



    Q3 FY24



    Y/Y

    Revenue

    $54.9 billion



    $54.9 billion



    — %

    Operating earnings

    $730 million



    $369 million



    98 %

    Non-GAAP operating earnings

    $807 million



    $667 million



    21 %

    Net earnings attributable to Cardinal Health, Inc.

    $506 million



    $261 million



    94 %

    Non-GAAP net earnings attributable to Cardinal Health, Inc.

    $568 million



    $511 million



    11 %

    Effective Tax Rate

    23.6 %



    23.3 %





    Non-GAAP Effective Tax Rate

    22.4 %



    19.9 %





    Diluted EPS attributable to Cardinal Health, Inc.

    $2.10



    $1.07



    96 %

    Non-GAAP diluted EPS attributable to Cardinal Health, Inc.

    $2.35



    $2.09



    13 %

    Segment results

    Pharmaceutical and Specialty Solutions segment



    Q3 FY25



    Q3 FY24



    Y/Y

    Revenue

    $              50.4  billion



    $             50.6 billion



    — %

    Segment profit

    $               662 million



    $              582 million



    14 %

    Third quarter revenue for the Pharmaceutical and Specialty Solutions segment was relatively flat at $50.4 billion. Third quarter revenue increased 20% excluding the impact of the customer contract expiration, driven by brand and specialty pharmaceutical sales growth from existing and new customers.

    Pharmaceutical and Specialty Solutions segment profit increased 14% to $662 million in the third quarter, driven by contributions from brand and specialty products, MSO platforms (including GI Alliance), BioPharma Solutions (including Specialty Networks) and positive generics program performance. This growth was partially offset by the customer contract expiration.

    Global Medical Products and Distribution segment



    Q3 FY25



    Q3 FY24



    Y/Y

    Revenue

    $               3.2  billion



    $                3.1  billion



    2 %

    Segment profit

    $               39 million



    $                 22 million



    77 %

    Third quarter revenue for the Global Medical Products and Distribution segment increased 2% to $3.2 billion, driven by volume growth from existing customers.

    Global Medical Products and Distribution segment profit increased 77% to $39 million in the third quarter, driven by the beneficial net impact of cost optimization initiatives.

    Other3



    Q3 FY25



    Q3 FY24



    Y/Y

    Revenue

    $               1.3  billion



    $                1.2  billion



    13 %

    Segment profit

    $              134 million



    $               110 million



    22 %

    Third quarter revenue for Other increased 13% to $1.3 billion, driven by growth across the three operating segments: at-Home Solutions, Nuclear and Precision Health Solutions and OptiFreight Logistics.

    Other segment profit increased 22% to $134 million in the third quarter, driven by growth across the three operating segments: at-Home Solutions, OptiFreight Logistics and Nuclear and Precision Health Solutions.

    Fiscal year 2025 outlook2 

    The company raised and narrowed its fiscal 2025 guidance range for non-GAAP diluted earnings per share attributable to Cardinal Health, Inc. to $8.05 to $8.15, from $7.85 to $8.00. The updated fiscal 2025 guidance reflects:

    • Increased outlook for Pharmaceutical and Specialty Solutions segment profit to 11.5% to 12.5% growth, from 10% to 12% growth previously
    • Increased outlook for Other segment profit to 16% to 18% growth, from ~10% growth previously, driven by stronger organic performance and the completed acquisition of Advanced Diabetes Supply Group
    • Narrowed outlook for GMPD segment profit to $130 million to $140 million, from $130 million to $150 million previously
    • Narrowed outlook for interest and other expense to a range of $200 million to $215 million, from $200 million to $230 million previously
    • Narrowed outlook for non-GAAP effective tax rate of 23% to 23.5%, from 23% to 24% previously
    • Updated outlook for diluted weighted average shares outstanding to ~242 million, from ~243 million previously, reflecting recent share repurchases

    Fiscal year 2026 update2

    Cardinal Health anticipates double-digit non-GAAP EPS growth in fiscal 2026, despite the evolving macro environment conditions. The company continues to expect strong segment profit growth in Pharmaceutical and Specialty Solutions and across its three operating segments reported in Other. In the face of the macro uncertainty, the company is updating its expectations for fiscal 2026 GMPD segment profit, which it now expects to be at least consistent with fiscal 2025 segment profit. The company will continue to assess opportunities and risks and plans to further discuss its expectations for fiscal 2026 and beyond at its upcoming Investor Day on June 12, 2025.

    Recent highlights

    • GI Alliance bolstered its leading multi-specialty MSO platform by entering into the urology therapeutic area with agreements to acquire Urology America and Potomac Urology, furthering its strategy to support physician-led practices and deliver superior patient outcomes
    • Cardinal Health completed its acquisition of Advanced Diabetes Supply Group on April 1st. ADSG is a leading national direct-to-patient diabetes medical supplies provider that enhances at-Home Solutions' capabilities to service patients in their homes
    • Cardinal Health elected two new independent directors with extensive leadership experience to its board of directors: Robert Musslewhite, former CEO of Definitive Healthcare Corp. and Sudhakar Ramakrishna, President and CEO of SolarWinds Corporation
    • Cardinal Health completed a $375M accelerated share repurchase program during the third quarter
    • Cardinal Health announced that it has entered into an agreement with GE Healthcare to manufacture and distribute Flyrcado, a first-of-its-kind PET agent for enhanced diagnosis of coronary artery disease
    • Cardinal Health published its annual report on biosimilars, "10 years of biosimilars," highlighting the positive impact these medications have had on patients' lives and the healthcare ecosystem, as well as potential future benefits
    • Cardinal Health was named one of America's Most Innovative Companies by Fortune for the third consecutive year

    Webcast

    Cardinal Health will host a webcast today at 8:30 a.m. EST to discuss third quarter results. To access the webcast and corresponding slide presentation, go to the Investor Relations page at ir.cardinalhealth.com. No access code is required. 

    Presentation slides and a webcast replay will be available on the Investor Relations page for 12 months.

    About Cardinal Health

    Cardinal Health is a distributor of pharmaceuticals and specialty products; a global manufacturer and distributor of medical and laboratory products; a supplier of home-health and direct-to-patient products and services; an operator of nuclear pharmacies and manufacturing facilities; and a provider of performance and data solutions. Our company's customer-centric focus drives continuous improvement and leads to innovative solutions that improve people's lives every day. Learn more about Cardinal Health at cardinalhealth.com and in our Newsroom.

    Contacts

    Media: Erich Timmerman, [email protected] and 614.757.8231

    Investors: Matt Sims, [email protected] and 614.553.3661

    1GAAP refers to U.S. generally accepted accounting principles. This news release includes GAAP financial measures as well as non-GAAP financial measures, which are financial measures not calculated in accordance with GAAP. See "Use of Non-GAAP Measures" following the attached schedules for definitions of the non-GAAP financial measures presented in this news release and see the attached schedules for reconciliations of the differences between the non-GAAP financial measures and their most directly comparable GAAP financial measures.

    2The company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable significance of which cannot be determined, is not available and cannot be reasonably estimated. See "Use of Non-GAAP Measures" following the attached schedules for additional explanation.

    3Other includes the following three operating segments: Nuclear and Precision Health Solutions (NPHS), at-Home Solutions and OptiFreight Logistics, which are not significant enough individually to require reportable segment disclosure.

    Cardinal Health uses its website as a channel of distribution for material company information. Important information, including news releases, financial information, earnings and analyst presentations, and information about upcoming presentations and events is routinely posted and accessible on the Investor Relations page at ir.cardinalhealth.com. In addition, the website allows investors and other interested persons to sign up automatically to receive email alerts when the company posts news releases, SEC filings and certain other information on its website.

    Cautions Concerning Forward-Looking Statements

    This release contains forward-looking statements addressing expectations, prospects, estimates and other matters that are dependent upon future events or developments. These statements may be identified by words such as "expect," "anticipate," "intend," "plan," "believe," "will," "should," "could," "would," "project," "continue," "likely," and similar expressions, and include statements reflecting future results or guidance, statements of outlook and various accruals and estimates. These matters are subject to risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied. These risks and uncertainties include the risk that we may fail to achieve our strategic objectives, including the continued execution of the GMPD Improvement Plan initiatives, whether as a result of tariffs on products we source or manufacture, an uncertain global economic environment, Cardinal Health Brand sales or ongoing inflationary pressures; competitive pressures in Cardinal Health's various lines of business, including the risk that customers may reduce purchases made under their contracts with us or terminate or not renew their contracts, whether due to price increases or otherwise; our ability to manage uncertainties associated with the pricing of branded pharmaceuticals, including as a result of legislative or executive actions; risks associated with litigation matters, including a Department of Justice investigation focused on potential violations of the Anti-Kickback Statute and False Claims Act; the risk that events outside of our control, such as weather or geopolitical events, may impact demand for our products or may cause supply shortages that impact our cost and ability to fulfill customer demand; the performance of our generics program, including the amount or rate of generic deflation and our ability to offset generic deflation and maintain other financial and strategic benefits through our generic sourcing venture or other components of our generics programs; risks associated with recently completed and pending acquisitions, including risks arising as a result from our entry into new lines of businesses.. Cardinal Health is subject to additional risks and uncertainties described in Cardinal Health's Form 10-K, Form 10-Q and Form 8K reports and exhibits to those reports. This release reflects management's views as of May 1, 2025. Except to the extent required by applicable law, Cardinal Health undertakes no obligation to update or revise any forward-looking statement. Forward-looking statements are aspirational and not guarantees or promises that goals, targets or projections will be met, and no assurance can be given that any commitment, expectation, initiative or plan in this report can or will be achieved or completed. Cardinal Health provides definitions and reconciliations of non-GAAP financial measures and their most directly comparable GAAP financial measures at ir.cardinalhealth.com

     

    Schedule 1

    Cardinal Health, Inc. and Subsidiaries 

    Condensed Consolidated Statements of Earnings (Unaudited)





    Third  Quarter



    Year-to-Date

    (in millions, except per common share amounts)

    2025



    2024



    % Change



    2025



    2024



    % Change

    Revenue

    $        54,878



    $        54,868



    — %



    $       162,419



    $       166,960



    (3) %

    Cost of products sold

    52,755



    52,933



    — %



    156,453



    161,428



    (3) %

    Gross margin

    2,123



    1,935



    10 %



    5,966



    5,532



    8 %

























    Operating expenses:























    Distribution, selling, general and administrative expenses

    1,315



    1,269



    4 %



    3,898



    3,723



    5 %

    Restructuring and employee severance

    28



    53







    61



    106





    Amortization and other acquisition-related costs

    152



    80







    331



    207





    Acquisition-related cash and share-based compensation costs

    20



    —







    20



    —





    Impairments and (gain)/loss on disposal of assets, net 1

    (17)



    84







    (15)



    626





    Litigation (recoveries)/charges, net

    (105)



    80







    (176)



    28





    Operating earnings

    730



    369



    98 %



    1,847



    842



    N.M.

























    Other (income)/expense, net

    (9)



    (1)







    (11)



    (10)





    Interest expense, net

    74



    28



    N.M.



    141



    42



    N.M.

    Earnings before income taxes

    665



    342



    94 %



    1,717



    810



    N.M.

























    Provision for income taxes 2

    157



    80



    96 %



    391



    190



    N.M.

    Net earnings

    508



    262



    94 %



    1,326



    620



    N.M.

























    Less: Net earnings attributable to noncontrolling interests

    (2)



    (1)







    (4)



    (3)





    Net earnings attributable to Cardinal Health, Inc.

    $            506



    $            261



    94 %



    $          1,322



    $            617



    N.M.

























    Earnings per common share attributable to Cardinal Health, Inc.:























    Basic

    $           2.11



    $           1.07



    97 %



    $            5.47



    $           2.51



    N.M.

    Diluted

    2.10



    1.07



    96 %



    5.44



    2.50



    N.M.

























    Weighted-average number of common shares outstanding:























    Basic

    240



    243







    242



    245





    Diluted

    241



    245







    243



    247







    1 For the nine months ended March 31, 2024, impairments and (gain)/loss on disposal of assets, net included a pre-tax goodwill impairment charge of $675 million related to the GMPD segment.  

    2 For fiscal 2024, the net tax benefit related to the GMPD goodwill impairment charge was $56 million and was included in the annual effective tax rate. As a result, the amount of tax benefit increased by an incremental $36 million for the nine months ended March 31, 2024 and reversed in the fourth quarter of fiscal 2024.

     

    Schedule 2

    Cardinal Health, Inc. and Subsidiaries

    Condensed Consolidated Balance Sheets



    (in millions)

    March 31, 2025



    June 30, 2024

    Assets

    (Unaudited)





    Current assets:







    Cash and equivalents

    $               3,326



    $               5,133

    Trade receivables, net

    12,666



    12,084

    Inventories, net

    16,158



    14,957

    Prepaid expenses and other

    2,398



    2,663

    Assets held for sale

    47



    47

    Total current assets

    34,595



    34,884









    Property and equipment, net

    2,664



    2,529

    Goodwill and other intangibles, net

    11,014



    6,450

    Other assets

    1,598



    1,258

    Total assets

    $              49,871



    $              45,121









    Liabilities and Shareholders' Deficit







    Current liabilities:







    Accounts payable

    $              32,812



    $              31,759

    Current portion of long-term obligations and other short-term borrowings

    543



    434

    Other accrued liabilities

    3,307



    3,447

    Total current liabilities

    36,662



    35,640









    Long-term obligations, less current portion

    7,136



    4,658

    Deferred income taxes and other liabilities

    7,971



    8,035









    Total shareholders' deficit

    (1,898)



    (3,212)

    Total liabilities and shareholders' deficit

    $              49,871



    $              45,121

     

    Schedule 3

    Cardinal Health, Inc. and Subsidiaries

    Consolidated Statements of Cash Flows (Unaudited)





    Third  Quarter



    Year-to-Date

    (in millions)

    2025



    2024



    2025



    2024

    Cash flows from operating activities:















    Net earnings

    $                508



    $                262



    $              1,326



    $                620

















    Adjustments to reconcile net earnings to net cash provided by operating activities:















    Depreciation and amortization

    207



    177



    581



    524

    Impairments and loss on sale of other investments

    —



    —



    2



    —

    Impairments and (gain)/loss on disposal of assets, net

    (17)



    84



    (15)



    626

    Share-based compensation

    31



    31



    91



    88

    Provision for bad debts

    13



    7



    41



    28

    Change in operating assets and liabilities, net of effects from acquisitions and divestitures:















     (Increase)/decrease in trade receivables

    (114)



    257



    (367)



    (223)

     (Increase)/decrease in inventories

    758



    1,191



    (1,209)



    (1,258)

     Increase/(decrease) in accounts payable

    1,424



    (2,235)



    954



    2,118

     Other accrued liabilities and operating items, net

    107



    199



    (534)



    (843)

    Net cash provided by/(used in) operating activities

    2,917



    (27)



    870



    1,680

















    Cash flows from investing activities:















    Acquisition of subsidiaries, net of cash acquired

    (2,779)



    (1,192)



    (3,855)



    (1,192)

    Proceeds from divestitures, net of cash sold

    —



    —



    2



    9

    Additions to property and equipment

    (126)



    (112)



    (315)



    (318)

    Proceeds from the disposal of property and equipment

    3



    8



    3



    10

    Purchases of investments

    (3)



    (1)



    (6)



    (3)

    Proceeds from investments

    5



    —



    7



    1

    Proceeds from net investment hedge terminations

    2



    —



    2



    28

    Purchase of short-term time deposits

    —



    (550)



    —



    (550)

    Proceeds from short-term investment in time deposit

    —



    —



    200



    —

    Net cash used in investing activities

    (2,898)



    (1,847)



    (3,962)



    (2,015)

















    Cash flows from financing activities:















    Proceeds from long-term obligations, net of issuance costs

    —



    1,139



    2,869



    1,139

    Reduction of long-term obligations

    (11)



    (8)



    (434)



    (23)

    Net tax proceeds/(withholding) from share-based compensation

    3



    22



    (12)



    23

    Dividends on common shares

    (124)



    (122)



    (374)



    (377)

    Purchase of treasury shares, net

    (375)



    —



    (765)



    (750)

    Net cash provided by/(used in) financing activities

    (507)



    1,031



    1,284



    12

















    Effect of exchange rate changes on cash and equivalents

    4



    (8)



    1



    (7)

















    Net decrease in cash and equivalents

    (484)



    (851)



    (1,807)



    (330)

    Cash and equivalents at beginning of period

    3,810



    4,597



    5,133



    4,076

    Cash and equivalents at end of period

    $              3,326



    $              3,746



    $              3,326



    $              3,746

     

    Schedule 4

    Cardinal Health, Inc. and Subsidiaries

    Segment Information





    Third Quarter



























    Pharmaceutical and Specialty Solutions



    Global Medical Products and Distribution



    Other

    (in millions)

    2025



    2024



    2025



    2024



    2025



    2024

    Revenue























    Amount

    $             50,433



    $             50,622



    $               3,160



    $               3,113



    $               1,304



    $               1,154

    Growth rate

    — %



    9 %



    2 %



    3 %



    13 %



    14 %

























    Segment profit























    Amount

    $                 662



    $                 582



    $                   39



    $                   22



    $                 134



    $                 110

    Growth rate

    14 %



    — %



    77 %



    N.M.



    22 %



    9 %

    Segment profit margin

    1.31 %



    1.15 %



    1.23 %



    0.71 %



    10.28 %



    9.53 %





    Year-to-Date



























    Pharmaceutical and Specialty Solutions



    Global Medical Products and Distribution



    Other

    (in millions)

    2025



    2024



    2025



    2024



    2025



    2024

    Revenue























    Amount

    $           149,272



    $           154,412



    $               9,437



    $               9,272



    $               3,773



    $               3,340

    Growth rate

    (3) %



    11 %



    2 %



    1 %



    13 %



    11 %

























    Segment profit























    Amount

    $               1,723



    $               1,533



    $                   65



    $                   45



    $                 356



    $                 312

    Growth rate

    12 %



    7 %



    44 %



    N.M.



    14 %



    5 %

    Segment profit margin

    1.15 %



    0.99 %



    0.69 %



    0.49 %



    9.44 %



    9.34 %



    The sum of the components and certain computations may reflect rounding adjustments.

     

    Schedule 5

    Cardinal Health, Inc. and Subsidiaries

    GAAP / Non-GAAP Reconciliation1





















    Net





























    Earnings















    Gross







    Operating

    Earnings

    Provision

    Attributable



    Net





    Diluted





    Margin



    SG&A2



    Earnings

    Before

    for

    to Non-



    Earnings3

    Effective



    EPS 3

    (in millions, except per common share amounts)

    Gross

    Growth



    Growth

    Operating

    Growth

    Income

    Income

    controlling

    Net

    Growth

    Tax

    Diluted

    Growth

    Margin

    Rate

    SG&A2

    Rate

    Earnings

    Rate

    Taxes

    Taxes

    Interests

    Earnings3

    Rate

    Rate

    EPS 3

    Rate

    Third Quarter 2025

    GAAP

    $  2,123

    10 %

    $ 1,315

    4 %

    $       730

    98 %

    $      665

    $       157

    $            (2)

    $       506

    94 %

    23.6 %

    $   2.10

    96 %

    Restructuring and employee severance

    —



    —



    28



    28

    7

    —

    21





    0.09



    Amortization and other acquisition-related costs

    —



    —



    152



    152

    34

    (2)

    116





    0.48



    Acquisition-related cash & share-based compensation costs

    —



    —



    20



    20

    1

    (4)

    15





    0.06



    Impairments and (gain)/loss on disposal of assets, net

    —



    —



    (17)



    (17)

    (4)

    —

    (13)





    (0.06)



    Litigation (recoveries)/charges, net

    —



    —



    (105)



    (105)

    (27)

    —

    (78)





    (0.32)



    Non-GAAP

    $  2,122

    10 %

    $ 1,315

    4 %

    $       807

    21 %

    $      741

    $       166

    $            (7)

    $       568

    11 %

    22.4 %

    $   2.35

    13 %

































    Third Quarter 2024

    GAAP

    $  1,935

    7 %

    $ 1,269

    8 %

    $       369

    (39) %

    $      342

    $         80

    $            (1)

    $       261

    (28) %

    23.3 %

    $   1.07

    (24) %

    Shareholder cooperation agreement costs

    —



    (1)



    1



    1

    —

    —

    1





    —



    Restructuring and employee severance

    —



    —



    53



    53

    14

    —

    39





    0.16



    Amortization and other acquisition-related costs

    —



    —



    80



    80

    21

    —

    59





    0.24



    Impairments and (gain)/loss on disposal of assets, net 4

    —



    —



    84



    84

    (21)

    —

    105





    0.44



    Litigation (recoveries)/charges, net

    —



    —



    80



    80

    34

    —

    46





    0.18



    Non-GAAP

    $  1,935

    7 %

    $ 1,269

    8 %

    $       667

    5 %

    $      640

    $       128

    $            (1)

    $       511

    8 %

    19.9 %

    $   2.09

    14 %



    1 For more information on these measures, refer to the Use of Non-GAAP Measures and Definitions schedules. 

    2 Distribution, selling, general and administrative expenses.  

    3 Attributable to Cardinal Health, Inc. 

    4 For the three months ended March 31, 2024, impairments and (gain)/loss on disposal of assets, net includes a pre-tax goodwill impairment charge of $90 million related to the GMPD segment. For fiscal 2024, the estimated net tax benefit related to the impairment was included in the annual effective tax rate. As a result, the amount of tax expense recognized increased approximately by an incremental $30 million during the three months ended March 31, 2024.

    The sum of the components and certain computations may reflect rounding adjustments. 

    We generally apply varying tax rates depending on the item's nature and tax jurisdiction where it is incurred. 

     

    Schedule 5

    Cardinal Health, Inc. and Subsidiaries

    GAAP / Non-GAAP Reconciliation1





















    Net





























    Earnings















    Gross







    Operating

    Earnings

    Provision

    Attributable



    Net





    Diluted





    Margin



    SG&A2



    Earnings

    Before

     for

    to Non-



    Earnings3

    Effective



    EPS 3

    (in millions, except per common share amounts)

    Gross

    Growth



    Growth

    Operating

    Growth

    Income

    Income

    controlling

    Net

    Growth

    Tax

    Diluted

    Growth

    Margin

    Rate

    SG&A2

    Rate

    Earnings

    Rate

    Taxes

    Taxes

    Interests

    Earnings3

    Rate

    Rate

    EPS 3

    Rate

    Year-to-Date 2025

    GAAP

    $ 5,966

    8 %

    $ 3,898

    5 %

    $     1,847

    N.M.

    $    1,717

    $       391

    $            (4)

    $     1,322

    N.M.

    22.8 %

    $   5.44

    N.M.

    Restructuring and employee severance

    —



    —



    61



    61

    15

    —

    46





    0.19



    Amortization and other acquisition-related costs

    —



    —



    331



    331

    81

    (2)

    248





    1.02



    Acquisition-related cash & share-based compensation costs

    —



    —



    20



    20

    1

    (4)

    15





    0.06



    Impairments and (gain)/loss on disposal of assets, net

    —



    —



    (15)



    (15)

    (4)

    —

    (11)





    (0.04)



    Litigation (recoveries)/charges, net

    —



    —



    (176)



    (176)

    (51)

    —

    (125)





    (0.51)



    Non-GAAP

    $ 5,966

    8 %

    $ 3,898

    5 %

    $     2,067

    14 %

    $    1,937

    $       431

    $          (10)

    $     1,495

    6 %

    22.3 %

    $   6.16

    8 %

































    Year-to-Date 2024

    GAAP

    $ 5,532

    9 %

    $ 3,723

    5 %

    $       842

    31 %

    $      810

    $       190

    $            (3)

    $       617

    60 %

    23.4 %

    $   2.50

    71 %

    Shareholder cooperation agreement costs

    —



    (1)



    1



    1

    —

    —

    1





    —



    Restructuring and employee severance

    —



    —



    106



    106

    28

    —

    78





    0.32



    Amortization and other acquisition-related costs

    —



    —



    207



    207

    55

    —

    152





    0.62



    Impairments and (gain)/loss on disposal of assets, net 4

    —



    —



    626



    626

    79

    —

    547





    2.21



    Litigation (recoveries)/charges, net

    —



    —



    28



    28

    17

    —

    11





    0.04



    Non-GAAP

    $ 5,532

    9 %

    $ 3,723

    5 %

    $     1,809

    17 %

    $    1,777

    $       369

    $            (3)

    $     1,405

    20 %

    20.7 %

    $   5.69

    29 %



    1 For more information on these measures, refer to the Use of Non-GAAP Measures and Definitions schedules. 

    2 Distribution, selling, general and administrative expenses.  

    3 Attributable to Cardinal Health, Inc. 

    4 For the nine months ended March 31, 2024, impairments and (gain)/loss on disposal of assets, net included pre-tax impairment charges of $675 million related to the GMPD segment. For fiscal 2024, the net tax benefit related to these charges was $56 million and was included in the annual effective tax rate. As a result, the amount of tax expense recognized increased approximately by an incremental $36 million during the nine months ended March 31, 2024.

    The sum of the components and certain computations may reflect rounding adjustments. 

    We generally apply varying tax rates depending on the item's nature and tax jurisdiction where it is incurred.

     

    Schedule 6

    Cardinal Health, Inc. and Subsidiaries

    GAAP / Non-GAAP Reconciliation - GAAP Cash Flow to Non-GAAP Adjusted Free Cash Flow





















    Third Quarter



    Year-to-Date

    (in millions)

    2025



    2024



    2025



    2024

    GAAP - Cash Flow Categories















    Net cash provided by/(used in) operating activities

    $            2,917



    $                (27)



    $               870



    $              1,680

    Net cash used in investing activities

    (2,898)



    (1,847)



    (3,962)



    (2,015)

    Net cash provided by/(used in) financing activities

    (507)



    1,031



    1,284



    12

    Effect of exchange rates changes on cash and equivalents

    4



    (8)



    1



    (7)

    Net decrease in cash and equivalents

    $              (484)



    $              (851)



    $          (1,807)



    $               (330)

















    Non-GAAP Adjusted Free Cash Flow















    Net cash provided by/(used in) operating activities

    $            2,917



    $                (27)



    $              870



    $             1,680

    Additions to property and equipment

    (126)



    (112)



    (315)



    (318)

    Payments related to matters included in litigation (recoveries)/charges, net

    1



    246



    622



    761

    Non-GAAP Adjusted Free Cash Flow

    $            2,792



    $               107



    $           1,177



    $            2,123



    For more information on these measures, refer to the Use of Non-GAAP Measures and Definitions schedules. 

     

    Schedule 7

    Cardinal Health, Inc. and Subsidiaries

    Revenue Growth Rates Excluding OptumRx



    Third Quarter





























    Consolidated





    Pharmaceutical and Specialty Solutions

    (in millions)

    2025



    2024



    Growth

    Rate



    (in millions)

    2025



    2024



    Growth

    Rate

    Total Revenue

    $         54.9



    $         54.9



    — %



    Total Pharmaceutical and Specialty

    Solutions Revenue

    $         50.4



    $       50.6



    (4) %

    less: OptumRx Revenue

    —



    8.7







    less: OptumRx Revenue

    —



    8.7





    Revenue, excluding OptumRx

    $         54.9



    $         46.2



    19 %



    Pharmaceutical and Specialty Solutions

    Revenue, excluding OptumRx

    $         50.4



    $       41.9



    20 %



    Year-to-Date





























    Consolidated





    Pharmaceutical and Specialty Solutions

    (in millions)

    2025



    2024



    Growth

    Rate



    (in millions)

    2025



    2024



    Growth

    Rate

    Total Revenue

    $        162.4



    $        167.0



    (3) %



    Total Pharmaceutical and Specialty

    Solutions Revenue

    $        149.3



    $      154.4



    (3) %

    less: OptumRx Revenue

    —



    27.8







    less: OptumRx Revenue

    —



    27.8





    Revenue, excluding OptumRx

    $        162.4



    $        139.2



    17 %



    Pharmaceutical and Specialty Solutions

    Revenue, excluding OptumRx

    $        149.3



    $      126.6



    18 %

    Cardinal Health, Inc. and Subsidiaries

    Use of Non-GAAP Measures

    This earnings release contains financial measures that are not calculated in accordance with U.S. generally accepted accounting principles ("GAAP").

    In addition to analyzing our business based on financial information prepared in accordance with GAAP, we use these non-GAAP financial measures internally to evaluate our performance, engage in financial and operational planning, and determine incentive compensation because we believe that these measures provide additional perspective on and, in some circumstances are more closely correlated to, the performance of our underlying, ongoing business. We provide these non-GAAP financial measures to investors as supplemental metrics to assist readers in assessing the effects of items and events on our financial and operating results on a year-over-year basis and in comparing our performance to that of our competitors. However, the non-GAAP financial measures that we use may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies. The non-GAAP financial measures disclosed by us should not be considered a substitute for, or superior to, financial measures calculated in accordance with GAAP, and the financial results calculated in accordance with GAAP and reconciliations to those financial statements set forth below should be carefully evaluated. 

    Exclusions from Non-GAAP Financial Measures

    Management believes it is useful to exclude the following items from the non-GAAP measures presented in this report for its own and for investors' assessment of the business for the reasons identified below:

    • LIFO charges and credits are excluded because the factors that drive last-in first-out ("LIFO") inventory charges or credits, such as pharmaceutical manufacturer price appreciation or deflation and year-end inventory levels (which can be meaningfully influenced by customer buying behavior immediately preceding our fiscal year-end), are largely out of our control and cannot be accurately predicted. The exclusion of LIFO charges and credits from non-GAAP metrics facilitates comparison of our current financial results to our historical financial results and to our peer group companies' financial results. We did not recognize any LIFO charges or credits during the periods presented.
    • State opioid assessments related to prior fiscal years is the portion of state assessments for prescription opioid medications that were sold or distributed in periods prior to the period in which the expense is incurred. This portion is excluded from non-GAAP financial measures because it is retrospectively applied to sales in prior fiscal years and inclusion would obscure analysis of the current fiscal year results of our underlying, ongoing business. Additionally, while states' laws may require us to make payments on an ongoing basis, the portion of the assessment related to sales in prior periods are contemplated to be one-time, nonrecurring items. Income from state opioid assessments related to prior fiscal years represents reversals of accruals due to changes in estimates or when the underlying assessments were invalidated by a Court or reimbursed by manufacturers.
    • Shareholder cooperation agreement costs includes costs such as legal, consulting and other expenses incurred in relation to the agreement (the "Cooperation Agreement") entered into among Elliott Associates, L.P., Elliott International, L.P. (together, "Elliott") and Cardinal Health. These include costs incurred to negotiate and finalize the Cooperation Agreement and costs incurred by the Business Review Committee of the Board of Directors, formed under this Cooperation Agreement, tasked with undertaking a comprehensive review of our strategy, portfolio, capital allocation framework, and operations. We have excluded these costs from our non-GAAP metrics because they do not occur in or reflect the ordinary course of our ongoing business operations and may obscure analysis of trends and financial performance. The Cooperation Agreement expired in the second quarter of fiscal 2025.
    • Restructuring and employee severance costs are excluded because they are not part of the ongoing operations of our underlying business and include, but are not limited to, costs related to divestitures, closing and consolidating facilities, changing the way we manufacture or distribute our products, moving manufacturing of a product to another location, changes in production or business process outsourcing or insourcing, employee severance and realigning operations.
    • Amortization and other acquisition-related costs, which include transaction costs, integration costs, and changes in the fair value of contingent consideration obligations, are excluded because they are not part of the ongoing operations of our underlying business and to facilitate comparison of our current financial results to our historical financial results and to our peer group companies' financial results. Additionally, costs for amortization of acquisition-related intangible assets and amortization as a result of basis differences in equity method investments are non-cash amounts, which are variable in amount and frequency and are significantly impacted by the timing and size of acquisitions, so their exclusion facilitates comparison of historical, current and forecasted financial results. We also exclude other acquisition-related costs, which are directly related to an acquisition but do not meet the criteria to be recognized on the acquired entity's initial balance sheet as part of the purchase price allocation. These costs are also significantly impacted by the timing, complexity and size of acquisitions.
    • Acquisition-related cash and share-based compensation costs are incurred in connection with contingent cash payments or the issuance of share-based payment awards, which include service requirements, as a part of certain physician practice acquisitions. These costs are excluded because they are unrelated to the underlying operating results of our business and to facilitate comparison of our current financial results to our historical financial results and to our peer group companies' financial results. In addition, the magnitude of these expenses is significantly impacted by the timing and size of the acquisitions of physician practices.
    • Impairments and gain or loss on disposal of assets, net are excluded because they do not occur in or reflect the ordinary course of our ongoing business operations and are inherently unpredictable in timing and amount, and in the case of impairments, are non-cash amounts, so their exclusion facilitates comparison of historical, current and forecasted financial results.
    • Litigation recoveries or charges, net are excluded because they often relate to events that may have occurred in prior or multiple periods, do not occur in or reflect the ordinary course of our business and are inherently unpredictable in timing and amount.
    • Loss on early extinguishment of debt is excluded because it does not typically occur in the normal course of business and may obscure analysis of trends and financial performance. Additionally, the amount and frequency of this type of charge is not consistent and is significantly impacted by the timing and size of debt extinguishment transactions.

    The tax effect for each of the items listed above is determined using the tax rate and other tax attributes applicable to the item and the jurisdiction(s) in which the item is recorded. The gross, tax and net impact of each item are presented with our GAAP to non-GAAP reconciliations. 

    Non-GAAP adjusted free cash flow: We provide this non-GAAP financial measure as a supplemental metric to assist readers in assessing the effects of items and events on our cash flow on a year-over-year basis and in comparing our performance to that of our peer group companies. In calculating this non-GAAP metric, certain items are excluded from net cash provided by operating activities because they relate to significant and unusual or non-recurring events and are inherently unpredictable in timing and amount. We believe adjusted free cash flow is important to management and useful to investors as a supplemental measure as it indicates the cash flow available for working capital needs, debt repayments, dividend payments, share repurchases, strategic acquisitions, or other strategic uses of cash. A reconciliation of our GAAP financial results to Non-GAAP adjusted free cash flow is provided in Schedule 6 of the financial statement tables included with this release.

    Forward Looking Non-GAAP Measures

    In this document, the Company presents certain forward-looking non-GAAP metrics. The Company does not provide outlook on a GAAP basis because the items that the Company excludes from GAAP to calculate the comparable non-GAAP measure can be dependent on future events that are less capable of being controlled or reliably predicted by management and are not part of the Company's routine operating activities. Additionally, management does not forecast many of the excluded items for internal use and therefore cannot create or rely on outlook done on a GAAP basis.

    The occurrence, timing and amount of any of the items excluded from GAAP to calculate non-GAAP could significantly impact the Company's fiscal 2025 GAAP results. Over the past five fiscal years, the excluded items have impacted the Company's EPS from $3.49 to $18.06, which includes a $17.54 charge related to the opioid litigation we recognized in fiscal 2020.

    Definitions

    Growth rate calculation: growth rates in this report are determined by dividing the difference between current-period results and prior-period results by prior-period results.

    Interest and Other, net: other (income)/expense, net plus interest expense, net.

    Segment Profit: segment revenue minus (segment cost of products sold and segment distribution, selling, general and administrative expenses).

    Segment Profit margin: segment profit divided by segment revenue. 

    Non-GAAP gross margin: gross margin, excluding LIFO charges/(credits).

    Non-GAAP distribution, selling, general and administrative expenses or Non-GAAP SG&A: distribution, selling, general and administrative expenses, excluding state opioid assessment related to prior fiscal years and shareholder cooperation agreement costs.

    Non-GAAP operating earnings: operating earnings excluding (1) LIFO charges/(credits), (2) state opioid assessment related to prior fiscal years, (3) shareholder cooperation agreement costs, (4) restructuring and employee severance, (5) amortization and other acquisition-related costs, (6) acquisition-related cash and share-based compensation costs, (7) impairments and (gain)/loss on disposal of assets, net and (8) litigation (recoveries)/charges, net. 

    Non-GAAP earnings before income taxes: earnings before income taxes excluding (1) LIFO charges/(credits), (2) state opioid assessment related to prior fiscal years, (3) shareholder cooperation agreement costs, (4) restructuring and employee severance, (5) amortization and other acquisition-related costs, (6) acquisition-related cash and share-based compensation costs, (7) impairments and (gain)/loss on disposal of assets, net, (8) litigation (recoveries)/charges, net and (9) loss on early extinguishment of debt.

    Non-GAAP net earnings attributable to non-controlling interests: net earnings attributable to non-controlling interests excluding (1) LIFO charges/(credits), (2) state opioid assessment related to prior fiscal years, (3) shareholder cooperation agreement costs, (4) restructuring and employee severance, (5) amortization and other acquisition-related costs, (6) acquisition-related cash and share-based compensation costs, (7) impairments and (gain)/loss on disposal of assets, net, (8) litigation (recoveries)/charges, net and (9) loss on early extinguishment of debt, each net of tax.

    Non-GAAP net earnings attributable to Cardinal Health, Inc.: net earnings attributable to Cardinal Health, Inc. excluding (1) LIFO charges/(credits), (2) state opioid assessment related to prior fiscal years, (3) shareholder cooperation agreement costs, (4) restructuring and employee severance, (5) amortization and other acquisition-related costs, (6) acquisition-related cash and share-based compensation costs, (7) impairments and (gain)/loss on disposal of assets, net, (8) litigation (recoveries)/charges, net and (9) loss on early extinguishment of debt, each net of tax.

    Non-GAAP effective tax rate: provision for income taxes adjusted for the tax impacts of (1) LIFO charges/(credits), (2) state opioid assessment related to prior fiscal years, (3) shareholder cooperation agreement costs, (4) restructuring and employee severance, (5) amortization and other acquisition-related costs, (6) acquisition-related cash and share-based compensation costs, (7) impairments and (gain)/loss on disposal of assets, net, (8) litigation (recoveries)/charges, net and (9) loss on early extinguishment of debt divided by (earnings before income taxes adjusted for the items above).

    Non-GAAP diluted earnings per share attributable to Cardinal Health, Inc.: non-GAAP net earnings attributable to Cardinal Health, Inc. divided by diluted weighted-average shares outstanding. 

    Non-GAAP adjusted free cash flow: net cash provided by/(used in) operating activities less payments related to additions to property and equipment, excluding settlement payments and receipts related to matters included in litigation (recoveries)/charges, net, as defined above, or other significant and unusual or non-recurring cash payments or receipts.

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/cardinal-health-reports-third-quarter-fiscal-year-2025-results-and-raises-fiscal-year-2025-outlook-302443934.html

    SOURCE Cardinal Health, Inc.

    Get the next $CAH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CAH

    DatePrice TargetRatingAnalyst
    2/5/2025$140.00 → $150.00Hold → Buy
    Jefferies
    1/8/2025$130.00 → $144.00Hold → Buy
    TD Cowen
    1/7/2025$140.00In-line → Outperform
    Evercore ISI
    1/6/2025$132.00 → $145.00Neutral → Buy
    BofA Securities
    12/13/2024$101.00 → $127.00Underweight → Equal Weight
    Wells Fargo
    12/4/2024$139.00Outperform
    Mizuho
    2/26/2024$125.00Outperform
    Leerink Partners
    2/9/2024Hold → Buy
    Argus
    More analyst ratings

    $CAH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cardinal Health upgraded by Jefferies with a new price target

      Jefferies upgraded Cardinal Health from Hold to Buy and set a new price target of $150.00 from $140.00 previously

      2/5/25 7:09:45 AM ET
      $CAH
      Other Pharmaceuticals
      Health Care
    • Cardinal Health upgraded by TD Cowen with a new price target

      TD Cowen upgraded Cardinal Health from Hold to Buy and set a new price target of $144.00 from $130.00 previously

      1/8/25 7:36:58 AM ET
      $CAH
      Other Pharmaceuticals
      Health Care
    • Cardinal Health upgraded by Evercore ISI with a new price target

      Evercore ISI upgraded Cardinal Health from In-line to Outperform and set a new price target of $140.00

      1/7/25 7:44:30 AM ET
      $CAH
      Other Pharmaceuticals
      Health Care

    $CAH
    Financials

    Live finance-specific insights

    See more
    • Cardinal Health Board of Directors Approves Quarterly Dividend

      DUBLIN, Ohio, May 5, 2025 /PRNewswire/ -- Cardinal Health (NYSE:CAH) announced today that its Board of Directors approved an increase to its quarterly dividend, to $0.5107 per share, out of the Company's capital surplus. The dividend will be payable on July 15, 2025, to shareholders of record at the close of business on July 1, 2025. About Cardinal HealthCardinal Health is a distributor of pharmaceuticals and specialty products; a global manufacturer and distributor of medical and laboratory products; a supplier of home-health and direct-to-patient products and services; an op

      5/5/25 5:30:00 PM ET
      $CAH
      Other Pharmaceuticals
      Health Care
    • Cardinal Health Reports Third Quarter Fiscal Year 2025 Results and Raises Fiscal Year 2025 Outlook

      Revenue was flat at $54.9 billion; revenue increased 19% excluding the impact of the previously communicated customer contract expirationGAAP1 operating earnings were $730 million; GAAP diluted EPS was $2.10Non-GAAP operating earnings increased 21% to $807 million, driven by segment profit growth across all of the company's operating segments; non-GAAP diluted EPS increased 13% to $2.35Fiscal year 2025 non-GAAP EPS guidance2 raised and narrowed to $8.05 to $8.15, from $7.85 to $8.00GI Alliance announces expansion into urology specialty therapeutic areaDUBLIN, Ohio, May 1, 2025 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today reported third quarter fiscal year 2025 revenues of $54.9 billion,

      5/1/25 6:45:00 AM ET
      $CAH
      Other Pharmaceuticals
      Health Care
    • Cardinal Health Board of Directors Approves Quarterly Dividend

      DUBLIN, Ohio, Feb. 3, 2025 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today that its Board of Directors approved a quarterly dividend of $0.5056 per share out of the Company's capital surplus. The dividend will be payable on April 15, 2025, to shareholders of record at the close of business on April 1, 2025. About Cardinal HealthCardinal Health is a distributor of pharmaceuticals and specialty products; a global manufacturer and distributor of medical and laboratory products; a supplier of home-health and direct-to-patient products and services; an operator of nucle

      2/3/25 5:15:00 PM ET
      $CAH
      Other Pharmaceuticals
      Health Care

    $CAH
    SEC Filings

    See more
    • SEC Form SD filed by Cardinal Health Inc.

      SD - CARDINAL HEALTH INC (0000721371) (Filer)

      5/22/25 8:34:09 AM ET
      $CAH
      Other Pharmaceuticals
      Health Care
    • SEC Form 10-Q filed by Cardinal Health Inc.

      10-Q - CARDINAL HEALTH INC (0000721371) (Filer)

      5/1/25 8:53:18 AM ET
      $CAH
      Other Pharmaceuticals
      Health Care
    • Cardinal Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - CARDINAL HEALTH INC (0000721371) (Filer)

      5/1/25 6:49:54 AM ET
      $CAH
      Other Pharmaceuticals
      Health Care

    $CAH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Carlisle Companies Announces Leadership Appointments

      Carlisle Companies Incorporated (NYSE:CSL) today announced the appointment of Christopher B. Gaskill as Vice President & General Counsel for the Company. In conjunction with this appointment, Scott C. Selbach will transition to a new role as Executive Vice President, Government Relations for the Company. Mr. Selbach will also remain Secretary of the Company. Both Mr. Gaskill and Mr. Selbach will report to Chris Koch, Carlisle's Chair, President & Chief Executive Officer. Prior to joining Carlisle, Mr. Gaskill served as Executive Vice President, Chief Legal Officer, and Secretary at Summit Materials, Inc. (NYSE:SUM), where he was responsible for the company's global legal functions and ensu

      5/16/25 4:05:00 PM ET
      $CAH
      $CSL
      $SUM
      $WU
      Other Pharmaceuticals
      Health Care
      Specialty Chemicals
      Industrials
    • Cardinal Health releases new report on the cell and gene therapy industry

      Analysis charts the emergence and future of advanced therapies DUBLIN, Ohio, May 7, 2025 /PRNewswire/ -- Today, Cardinal Health (NYSE:CAH) released its 2025 Advanced Therapies Report: Revolutionizing patient care – the promise and potential of cell and gene therapies, providing insights into the evolving landscape of cell and gene therapies (CGTs). This inaugural report is based on a comprehensive survey of more than 100 healthcare providers as well as interviews with subject matter experts and a patient who received CAR T-cell therapy, all of whom provide valuable insights in

      5/7/25 7:30:00 AM ET
      $CAH
      Other Pharmaceuticals
      Health Care
    • Cardinal Health Board of Directors Approves Quarterly Dividend

      DUBLIN, Ohio, May 5, 2025 /PRNewswire/ -- Cardinal Health (NYSE:CAH) announced today that its Board of Directors approved an increase to its quarterly dividend, to $0.5107 per share, out of the Company's capital surplus. The dividend will be payable on July 15, 2025, to shareholders of record at the close of business on July 1, 2025. About Cardinal HealthCardinal Health is a distributor of pharmaceuticals and specialty products; a global manufacturer and distributor of medical and laboratory products; a supplier of home-health and direct-to-patient products and services; an op

      5/5/25 5:30:00 PM ET
      $CAH
      Other Pharmaceuticals
      Health Care

    $CAH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $CAH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form SC 13G/A filed by Cardinal Health Inc. (Amendment)

      SC 13G/A - CARDINAL HEALTH INC (0000721371) (Subject)

      2/13/24 5:01:02 PM ET
      $CAH
      Other Pharmaceuticals
      Health Care
    • SEC Form SC 13G/A filed by Cardinal Health Inc. (Amendment)

      SC 13G/A - CARDINAL HEALTH INC (0000721371) (Subject)

      1/30/24 1:39:03 PM ET
      $CAH
      Other Pharmaceuticals
      Health Care
    • SEC Form SC 13G/A filed by Cardinal Health Inc. (Amendment)

      SC 13G/A - CARDINAL HEALTH INC (0000721371) (Subject)

      2/14/23 12:37:58 PM ET
      $CAH
      Other Pharmaceuticals
      Health Care
    • Director Ramakrishna Sudhakar was granted 1,049 shares (SEC Form 4)

      4 - CARDINAL HEALTH INC (0000721371) (Issuer)

      3/18/25 4:24:07 PM ET
      $CAH
      Other Pharmaceuticals
      Health Care
    • Director Musslewhite Robert W was granted 1,049 shares (SEC Form 4)

      4 - CARDINAL HEALTH INC (0000721371) (Issuer)

      3/18/25 4:20:20 PM ET
      $CAH
      Other Pharmaceuticals
      Health Care
    • New insider Ramakrishna Sudhakar claimed no ownership of stock in the company (SEC Form 3)

      3 - CARDINAL HEALTH INC (0000721371) (Issuer)

      3/11/25 4:11:05 PM ET
      $CAH
      Other Pharmaceuticals
      Health Care

    $CAH
    Leadership Updates

    Live Leadership Updates

    See more
    • Carlisle Companies Announces Leadership Appointments

      Carlisle Companies Incorporated (NYSE:CSL) today announced the appointment of Christopher B. Gaskill as Vice President & General Counsel for the Company. In conjunction with this appointment, Scott C. Selbach will transition to a new role as Executive Vice President, Government Relations for the Company. Mr. Selbach will also remain Secretary of the Company. Both Mr. Gaskill and Mr. Selbach will report to Chris Koch, Carlisle's Chair, President & Chief Executive Officer. Prior to joining Carlisle, Mr. Gaskill served as Executive Vice President, Chief Legal Officer, and Secretary at Summit Materials, Inc. (NYSE:SUM), where he was responsible for the company's global legal functions and ensu

      5/16/25 4:05:00 PM ET
      $CAH
      $CSL
      $SUM
      $WU
      Other Pharmaceuticals
      Health Care
      Specialty Chemicals
      Industrials
    • Robert Musslewhite and Sudhakar Ramakrishna to join Cardinal Health Board of Directors

      DUBLIN, Ohio, March 10, 2025 /PRNewswire/ -- Cardinal Health (NYSE:CAH) announced today that its Board of Directors has elected Robert Musslewhite, former Chief Executive Officer of Definitive Healthcare Corp., and Sudhakar Ramakrishna, President and Chief Executive Officer of SolarWinds Corporation, as independent directors, effective March 7, 2025. With more than 20 years of leadership experience, including serving as CEO for two publicly traded companies, Mr. Musslewhite brings to the board unique expertise in advanced analytics, data, and technology across the healthcare e

      3/10/25 6:45:00 AM ET
      $CAH
      Other Pharmaceuticals
      Health Care
    • RPM Announces Appointment of Three New Board Members

      RPM International Inc. (NYSE:RPM) today announced the appointment of three individuals, Craig S. Morford, Christopher L. Mapes and Julie A. Beck, to its board of directors. These appointments reflect RPM's ongoing commitment to expanding the expertise, diversity and leadership capabilities of its board as the company continues to drive long-term growth and shareholder value. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250113146614/en/Christopher L. Mapes (Photo: Business Wire) The appointments of Mr. Morford and Mr. Mapes are effective immediately, and Ms. Beck's term is set to commence on April 7, 2025. With these additions,

      1/13/25 4:45:00 PM ET
      $AOS
      $CAH
      $LECO
      $NDSN
      Consumer Electronics/Appliances
      Consumer Discretionary
      Other Pharmaceuticals
      Health Care